Treating Cholangiopathy

Nanoparticles of N-Acetyl-Cysteine for treatment of biliary duct diseases, which may lead to serious liver damage


A myocardial infarction, or heart attack, occurs when part of the heart muscle doesn’t receive enough blood flow due to a blockage, usually a blood clot. This blockage deprives the affected area of oxygen and nutrients, leading to the death of heart muscle cells. The extent of damage depends on factors like the location and duration of the blockage. A heart attack can result in necrosis (cell death) of heart tissue, the formation of scar tissue, impaired heart function, and potential complications like arrhythmias and heart failure.


Dr. Orit Waisbourd-Zinman, Schneider Children's Medical Center

Contact info

Sari Prutchi Sagiv PhD. Director of Pharma and Diagnostics

For further information please contact:

We have developed a novel, non-toxic, cardio-protective peptidomimetic (small molecule) candidate that ameliorates myocardial infarction (MI) .
We investigated the ability of the synthetized peptidomimetics to reduce both hypoxic and septic-like cardio-damage in vitro and in vivo. In several cardiac damage models our novel peptidomimetics showed very promising biological results, including:
The survival rate, measured at 24 hours following MI in the treated group was 100% compared to 58% of the controls subjected to MI .
The Infarct size was significantly smaller following 7 days in the treated group.
Enzymes leakage at 7 days following MI (CK LDH and Troponin) was significantly lower in the LT 87 treated group when compared to the controls.

Myocardial infarction is a significant health issue worldwide, and the market related to its treatment and management is of a substantial size. The prevalence of the disease approaches three million people worldwide, with more than one million deaths in the United States annually.

Contact Mor Research

You are welcomed to get in touch with us or leave us your details and we will come back to you as soon as possible.